2.71
Jaguar Health Inc 주식(JAGX)의 최신 뉴스
Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts - Marco Eagle
Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts | JAGX Stock News - GuruFocus
Jaguar Health CEO Reveals Near-Term Catalysts at Emerging Growth Conference Tomorrow - Stock Titan
Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - The Courier-Journal
First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs - The Oklahoman
Jaguar Health (JAGX) Advances Canalevia-CA1 Field Study for Cani - GuruFocus
First Study Site Established for Jaguar Health Study of its FDA - GuruFocus
Jaguar Health Establishes First Site for Canalevia-CA1 Field Study - MarketScreener
Jaguar Health (JAGX) Advances Canalevia-CA1 Field Study for Canine Treatment | JAGX Stock News - GuruFocus
First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs | JAGX Stock News - GuruFocus
First FDA-Approved Dog Diarrhea Treatment Targets 6M Annual Cases with New Clinical Study - Stock Titan
Jaguar Health, Inc. (NASDAQ:JAGX) Q1 2025 Earnings Call Transcript - MSN
REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners’ Spring 2025 Spotlight Series - The Oklahoman
Jaguar Health Reports First Quarter 2025 Financials - The Columbus Dispatch
Jaguar Health Provides Update on Meeting with FDA Discussing Sta - GuruFocus
Jaguar Health Eyes FDA Orphan Drug Designation for Crofelemer By Investing.com - Investing.com South Africa
Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer - Akron Beacon Journal
REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners' Spring 2025 Spotlight Series | JAGX Stock News - GuruFocus
Jaguar Health to Reveal Critical FDA Feedback on Breakthrough Phase 3 Breast Cancer Trial Results - Stock Titan
Jaguar Health (JAGX) Advances Plans for Crofelemer Application | - GuruFocus
New to The Street's Documentary Specials Break Records: IMG Academy Surpasses 126,000 Views in Just 12 Days - The Columbus Dispatch
Jaguar Health (JAGX) Advances Plans for Crofelemer Application | JAGX Stock News - GuruFocus
Jaguar Health Eyes FDA Orphan Drug Designation for Crofelemer - Investing.com
Breakthrough: FDA Meeting Could Fast-Track New Breast Cancer Treatment Following Positive Trial Data - Stock Titan
Jaguar Health to Host Investor Call Monday, November 16th at 8:30 a.m. Eastern Regarding Q3 2020 Financials & Business Updates - ACCESS Newswire
Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners’ Spring 2025 Spotlight Series - Detroit Free Press
Small-cap biotech Jaguar Health’s stock jumps as it launches treatment for a painful side effect of cancer treatment - MSN
자본화:
|
볼륨(24시간):